Furthermore, clinical trials of immunotherapy in several cancer types, including bladder cancer, and non-small cell lung cancer, have shown that elevated levels of a LRRC15 + CAF signature correlated with poor response to anti-PD-L1 therapy. This evidence concerns the gene LRRC15 and cancer.